Galantamine
Razadyne (galantamine) is a small molecule pharmaceutical. Galantamine was first approved as Razadyne on 2001-02-28. It is used to treat alzheimer disease in the USA. It is known to target acetylcholinesterase.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Razadyne (generic drugs available since 2008-08-28)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Galantamine hydrobromide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| RAZADYNE ER | Johnson & Johnson | N-021615 RX | 2005-04-01 | 3 products, RLD |
Show 2 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| galantamine | ANDA | 2023-05-31 |
| razadyne | New Drug Application | 2010-11-11 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| alzheimer disease | EFO_0000249 | D000544 | F03 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
32 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 1 | — | — | 3 | 8 | 12 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | — | 2 | — | 2 |
| Colorectal neoplasms | D015179 | — | — | — | 2 | — | 2 | ||
| Cognition | D003071 | EFO_0003925 | — | — | — | 1 | — | 1 | |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Magnetic resonance imaging | D008279 | — | — | 1 | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | — | — | — | — | 2 | 2 | |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | — | — | — | 2 | 2 |
| Diagnosis | D003933 | — | — | — | — | 1 | 1 | ||
| Dyspnea | D004417 | HP_0002094 | R06.0 | — | — | — | — | 1 | 1 |
| Colonic neoplasms | D003110 | C18 | — | — | — | — | 1 | 1 | |
| Diagnostic imaging | D003952 | — | — | — | — | 1 | 1 | ||
| Adenoma | D000236 | — | — | — | — | 1 | 1 | ||
| Liver abscess | D008100 | HP_0100523 | K75.0 | — | — | — | — | 1 | 1 |
| Liver failure | D017093 | HP_0001399 | K72.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | GALANTAMINE |
| INN | galantamine |
| Description | Galanthamine is a benzazepine alkaloid isolated from certain species of daffodils. It has a role as an antidote to curare poisoning, an EC 3.1.1.7 (acetylcholinesterase) inhibitor, a cholinergic drug, an EC 3.1.1.8 (cholinesterase) inhibitor and a plant metabolite. It is an organic heterotetracyclic compound, a tertiary amino compound, a benzazepine alkaloid and a benzazepine alkaloid fundamental parent. It is a conjugate base of a galanthamine(1+). |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | COc1ccc2c3c1O[C@H]1C[C@@H](O)C=C[C@@]31CCN(C)C2 |
Target
Agency Approved
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,810 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
555 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more